Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment

Fig. 4

Effect of sorafenib and regorafenib on the EMT in HCC. Several signaling pathways contribute to EMT. Among them, sorafenib was shown to degrade the transforming growth-factor beta receptor 2 (TGFβ2), which further activates SMAD2 and SMAD3 and subsequently induces the EMT. Sorafenib was also suggested to inhibit STAT3 and SANI1 expression. Regorafenib has been shown to obstruct the progression of the EMT through STAT3 inhibition and a decrease in the expression of ID1 and SNAI1 in HCC

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us